Abstract
Autoimmune bullous skin disorders represent a group of severe, chronic skin diseases which are characterized by the presence of autoantibodies targeting distinct adhesionmolecules of the epidermis and dermoepidermal basement membrane zone leading to a loss of adhesive function of the target antigen(s) (Fig. 8.1). The appearance of blisters and erosions of the skin and/or mucous membranes is the leading clinical sign of autoimmune bullous skin disorders (Fig. 8.2). While histopathology reveals the location of the blister formation, the detection of tissue bound autoantibodies by immunofluorescent staining of uninvolved perilesional skin biopsies is mandatory for diagnosing autoimmune bullous skin disorders. Circulating autoantibodies can be visualized by indirect immunofluorescence using tissue substrates such as monkey esophagus and sodium chloride-split human skin. Based on the specificity of the targeted antigens, several clinically and immune serologically distinct bullous disorders have been defined (Fig. 8.2).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arin MJ, Engert A, Krieg T, Hunzelmann N (2005) Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 153: 620–625
Berookhim B, Fischer HD, Weinberg JM (2004) Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis 74(4):245–247
Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14:520–533
Edwards JCW, Cambridge G (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nature Rev Immunol 6:394–403
Feliciani C, Toto P, Amerio P, Pour SM, Coscione G, Shivji G, Wang B, Sauder DN (2000) In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol 114(1):71–77
Hertl M, Eming R, Veldman C (2006) T cell control of autoimmune bullous skin disorders. J Clin Invest 116:1159–1166
Howell SM, Bessinger GT, Altman CE, Belnap CM (2005) Rapid response of IgA pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil. J Am Acad Dermatol 53(3):541–543
Jacobi A, Manger B, Schuler G, Hertl M (2005) Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol. 153(2):448–449
Lin MH, Hsu CK, Lee JY (2005) Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 141(6): 680–682
Pardo J, Mercader P, Mahiques L, Sánchez-Carazo JL, Oliver V, Fortea JM (2005) Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 153(1):222–223
Rouziere AS, Kneitz C, Palanichamy A, Dorner T, Tony HP (2005) Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res Ther 7(4):R714–724
Sacher C, Rubbert A, Konig C, Scharffetter-Kochanek K, Krieg T, Hunzelmann N (2002) Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 46(1):113–115
Scheinfeld NA (2004) Comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat 15:280–294
Yamauchi PS, Lowe NJ, Gindi V (2006) Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 54(3 Suppl 2):S121–122
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Eming, R., Niedermeier, A., Pfütze, M., Jacobi, A., Hertl, M. (2007). Treating Autoimmune Bullous Skin Disorders with Biologics. In: Boehncke, WH., Radeke, H.H. (eds) Biologics in General Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-29018-6_8
Download citation
DOI: https://doi.org/10.1007/978-3-540-29018-6_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-29017-9
Online ISBN: 978-3-540-29018-6
eBook Packages: MedicineMedicine (R0)